NMT bounces ahead on demand from Roche
This article was originally published in Clinica
Livingston, Scotland device producer NMT Group beat analysts' sales expectations in the first four months of 2003, said CEO Roy Smith. Speaking at the company's AGM on May 6, he said that demand from trading partner Roche for the company's first-generation safety syringe had propelled the sales growth. Higher demand had been matched by higher production at the Livingston manufacturing plant, and with this had come reduced unit costs. The company continues to seek additional first-generation syringe business partners.